Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad5-TRP2
- Development stage
- Preclinical
- Lead developer
- Thomas Jefferson University
- Modality
- Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Intradermal
01
Overview
Ad5-TRP2 is a replication-deficient recombinant adenovirus serotype 5 (Ad5) viral vector vaccine encoding Tyrosinase-Related Protein 2 (TRP2), also known as dopachrome tautomerase (DCT). TRP2 is a melanocyte differentiation antigen that is frequently overexpressed in melanoma. The vaccine is designed to induce antigen-specific CD8+ T-cell immune responses against TRP2-expressing tumor cells. It has been primarily used as a preclinical research tool, notably at Thomas Jefferson University (Snook Lab), to investigate tumor immunology and T-cell memory in murine melanoma models. A related variant, Ad5-Trp2-PADRE, incorporates a pan DR epitope to provide CD4+ T-cell help and enhance the durability of the immune response.
- Other names
- Ad5-DCTAd-5-DCTAd 5-DCTadenovirus-TRP2 vaccineadenovirus-TRP-2 vaccineadenovirus-TRP 2 vaccine
Beyond the preview
Go deeper on Ad5-TRP2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad5-TRP2.